{"title":"加速审批的抗癌药物的长期疗效。","authors":"","doi":"10.1136/dtb.2025.000016","DOIUrl":null,"url":null,"abstract":"<p><p><b>Overview of:</b> Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. <i>JAMA</i> 2024;331:1471-9.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"132"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term outcomes for cancer drugs with accelerated approval.\",\"authors\":\"\",\"doi\":\"10.1136/dtb.2025.000016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Overview of:</b> Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. <i>JAMA</i> 2024;331:1471-9.</p>\",\"PeriodicalId\":11277,\"journal\":{\"name\":\"Drug and Therapeutics Bulletin\",\"volume\":\" \",\"pages\":\"132\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and Therapeutics Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/dtb.2025.000016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and Therapeutics Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/dtb.2025.000016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Long-term outcomes for cancer drugs with accelerated approval.
Overview of: Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. JAMA 2024;331:1471-9.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
